Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.
AI can improve cancer outcome predictions by generating synthetic molecular data from routine pathology images, according to new research ...
Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...
N2OFF, Inc. (NASDAQ: NITO) ('N2OFF” and the 'Company”), a drug discovery company that is also investing in solar energy ...
A new study published in Ecology Letters has uncovered the mechanisms underlying plant community assembly and biodiversity ...
Pharmaceutical Technology on MSN
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery
The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...
Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.
AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of ...
AI Impact explores why AI security has outgrown human oversight, plus pricing gains, health care insight and key AI moves in ...
Explore the groundbreaking AI genomics platform, Inference, launched by Variant Bio to enhance drug discovery using genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback